Exhibit 99.20
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions) THIRD QUARTER
Percent
Change
Operat
2007 2006 Total -ions Currency
Sales to customers
by segment of business
Consumer
U.S. $1,591 1,138 39.8 % 39.8 -
International 2,032 1,318 54.2 46.5 7.7
3,623 2,456 47.5 43.4 4.1
Pharmaceutical
U.S. 3,765 3,841 (2.0) (2.0) -
International 2,334 2,040 14.4 7.2 7.2
6,099 5,881 3.7 1.2 2.5
Med Devices & Diagnostics
U.S. 2,569 2,509 2.4 2.4 -
International 2,679 2,441 9.8 3.7 6.1
5,248 4,950 6.0 3.0 3.0
U.S. 7,925 7,488 5.8 5.8 -
International 7,045 5,799 21.5 14.7 6.8
Worldwide $14,970 13,287 12.7 % 9.7 3.0
(Unaudited; Dollars in Millions) NINE MONTHS
Percent
Change
Operat
2007 2006 Total -ions Currency
Sales to customers by
segment of business
Consumer
U.S. $4,782 3,391 41.0 % 41.0 -
International 5,901 3,818 54.6 48.1 6.5
10,683 7,209 48.2 44.8 3.4
Pharmaceutical
U.S. 11,659 11,224 3.9 3.9 -
International 6,810 6,093 11.8 5.6 6.2
18,469 17,317 6.7 4.5 2.2
Med Devices & Diagnostics
U.S. 7,772 7,619 2.0 2.0 -
International 8,214 7,497 9.6 4.3 5.3
15,986 15,116 5.8 3.2 2.6
U.S. 24,213 22,234 8.9 8.9 -
International 20,925 17,408 20.2 14.3 5.9
Worldwide $45,138 39,642 13.9 % 11.3 2.6
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions) THIRD QUARTER
Percent
Change
Operat
2007 2006 Total -ions Currency
Sales to customers
by geographic area
U.S. $7,925 7,488 5.8 % 5.8 -
Europe 3,765 3,098 21.5 13.3 8.2
Western Hemisphere excluding U.S. 1,195 901 32.6 24.9 7.7
Asia-Pacific, Africa 2,085 1,800 15.8 11.8 4.0
International 7,045 5,799 21.5 14.7 6.8
Worldwide $14,970 13,287 12.7 % 9.7 3.0
(Unaudited; Dollars in Millions) NINE MONTHS
Percent
Change
Operat
2007 2006 Total -ions Currency
Sales to customers
by geographic area
U.S. $24,213 22,234 8.9 % 8.9 -
Europe 11,485 9,464 21.4 13.1 8.3
Western Hemisphere excluding U.S. 3,372 2,599 29.7 25.2 4.5
Asia-Pacific, Africa 6,068 5,345 13.5 11.2 2.3
International 20,925 17,408 20.2 14.3 5.9
Worldwide $45,138 39,642 13.9 % 11.3 2.6
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions
Except Per Share Figures) THIRD QUARTER
2007 2006
Percent Percent Percent
to to Increase
Amount Sales Amount Sales (Decrease)
Sales to customers $14,970 100.0 $13,287 100.0 12.7
Cost of products sold 4,274 28.5 3,650 27.5 17.1
Selling, marketing and
administrative expenses 4,899 32.7 4,291 32.3 14.2
Research expense 1,834 12.3 1,719 12.9 6.7
In-process research &
development (IPR&D) - - 115 0.9
Restructuring expense 745 5.0 - -
Interest (income)expense, net (52) (0.3) (194) (1.5)
Other (income)expense, net 2 - 45 0.3
Earnings before provision for
taxes on income 3,268 21.8 3,661 27.6 (10.7)
Provision for taxes on income 720 4.8 901 6.8 (20.1)
Net earnings $2,548 17.0 $2,760 20.8 (7.7)
Net earnings per share
(Diluted) $0.88 $0.94 (6.4)
Average shares outstanding
(Diluted) 2,912.9 2,948.1
Effective tax rate 22.0 % 24.6 %
Adjusted earnings before
provision for taxes and net
earnings (A)
Earnings before
provision for taxes on
income $4,013 (1) 26.8 $3,776 (2) 28.4 6.3
Net earnings $3,076 (1) 20.5 $2,875 (2) 21.6 7.0
Net earnings per share
(Diluted) $1.06 (1) $0.98 (2) 8.2
Effective tax rate 23.3% 23.9%
(1) The difference between as reported earnings and as adjusted earnings
before provision for taxes on income, net earnings and net earnings
per share (diluted) is the exclusion of the restructuring expense of
$745 million, $528 million and $0.18 per share, respectively.
(2) The difference between as reported earnings and as adjusted earnings
before provision for taxes on income, net earnings and net earnings
per share (diluted) is the exclusion of IPR&D of $115 million with no
tax benefit and $0.04 per share, respectively.
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except
Per Share Figures) NINE MONTHS
Percent Percent Percent
to to Increase
Amount Sales Amount Sales (Decrease)
Sales to customers $45,138 100.0 $39,642 100.0 13.9
Cost of products sold 13,017 28.8 11,050 27.9 17.8
Selling, marketing and
administrative expenses 14,730 32.6 12,737 32.1 15.6
Research expense 5,352 11.9 5,079 12.8 5.4
In-process research &
development (IPR&D) 807 1.8 239 0.6
Restructuring expense 745 1.7 - -
Interest (income)expense, net (121) (0.3) (571) (1.4)
Other (income)expense, net (343) (0.8) (771) (2.0)
Earnings before provision for
taxes on income 10,951 24.3 11,879 30.0 (7.8)
Provision for taxes on income 2,749 6.1 2,994 7.6 (8.2)
Net earnings $8,202 18.2 $8,885 22.4 (7.7)
Net earnings per share
(Diluted) $2.81 $2.99 (6.0)
Average shares outstanding
(Diluted) 2,919.3 2,971.3
Effective tax rate 25.1 % 25.2 %
Adjusted earnings before
provision for taxes and net
earnings (A)
Earnings before provision
for taxes on income $12,503 (1) 27.7 $11,496 (2) 29.0 8.8
Net earnings $9,537 (1) 21.1 $8,748 (2) 22.1 9.0
Net earnings per share
(Diluted) $3.27 (1) $2.95 (2) 10.8
Effective tax rate 23.7% 23.9%
(1) The difference between as reported earnings and as adjusted earnings
before provision for taxes on income, net earnings and net earnings
per share (diluted) is the exclusion of IPR&D of $807 million with no
tax benefit and $0.28 per share respectively, and the exclusion of the
restructuring expense of $745 million, $528 million and $0.18 per
share, respectively.
(2) The difference between as reported earnings and as adjusted earnings
before provision for taxes on income, net earnings and net earnings
per share (diluted) is the exclusion of the Guidant acquisition
termination fee of $622 million, $368 million and $0.12 per share,
respectively, and the exclusion of IPR&D of $239 million, $231
million and $0.08 per share, respectively.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before
provision for taxes on income," "adjusted net earnings,"
"adjusted net earnings per share (diluted)," and "adjusted
effective tax rate" are non-GAAP financial measures and
should not be considered replacements for GAAP results. The
Company provides earnings before provision for taxes on
income, net earnings, net earnings per share (diluted), and
effective tax rate on an adjusted basis because management
believes that these measures provide useful information to
investors. Among other things, they may assist investors in
evaluating the Company's results of operations period over
period. In various periods, these measures may exclude such
items as business development activities (including IPR&D at
acquisition or upon attainment of milestones and any
extraordinary expenses), strategic developments (including
restructuring and product line changes), significant
litigation, and changes in applicable laws and regulations
(including significant accounting or tax matters). Special
items may be highly variable, difficult to predict, and of a
size that sometimes has substantial impact on the Company's
reported results of operations for a period. Management uses
these measures internally for planning, forecasting and
evaluating the performances of the Company's businesses,
including allocating resources and evaluating results
relative to employee performance compensation targets.
Unlike earnings before provision for taxes on income, net
earnings, net earnings per share (diluted), and effective
tax rate prepared in accordance with GAAP, adjusted earnings
before provision for taxes on income, adjusted net earnings,
adjusted net earnings per share (diluted), and adjusted
effective tax rate may not be comparable with the
calculation of similar measures for other companies. These
non-GAAP financial measures are presented solely to permit
investors to more fully understand how management assesses
the performance of the Company. The limitations of using
these non-GAAP financial measures as performance measures
are that they provide a view of the Company's results of
operations without including all events during a period,
such as the effects of an acquisition, merger-related or
other restructuring charges, or amortization of purchased
intangibles, and do not provide a comparable view of the
Company's performance to other companies in the health care
industry. Investors should consider non-GAAP financial
measures in addition to, and not as replacements for, or
superior to, measures of financial performance prepared in
accordance with GAAP.
REPORTED SALES vs. PRIOR PERIOD
$MM
THIRD QUARTER
% Change
2007 2006 Reported Operational(1) Currency
PHARMACEUTICAL SEGMENT (2)
ACIPHEX/PARIET
US 159 146 8.4% 8.4% -
Intl 179 161 11.6% 4.0% 7.6%
WW 338 307 10.1% 6.1% 4.0%
Anti-Psychotics (3)
US 674 635 6.3% 6.3% -
Intl 488 433 12.8% 5.6% 7.2%
WW 1,162 1,068 8.9% 6.0% 2.9%
CONCERTA
US 177 179 -1.2% -1.2% -
Intl 54 41 34.0% 24.8% 9.2%
WW 231 220 5.3% 3.6% 1.7%
DURAGESIC
US 107 138 -23.0% -23.0% -
Intl 202 204 -0.7% -6.5% 5.8%
WW 309 342 -9.7% -13.2% 3.5%
EPREX/PROCRIT
US 380 522 -27.1% -27.1% -
Intl 302 276 9.0% 1.0% 8.0%
WW 682 798 -14.6% -17.4% 2.8%
Hormonal Contraceptives
US 166 210 -21.2% -21.2% -
Intl 67 60 11.9% 4.1% 7.8%
WW 233 270 -13.9% -15.6% 1.7%
LEVAQUIN/FLOXIN
US 352 334 5.4% 5.4% -
Intl 19 13 46.2% 42.9% 3.8%
WW 371 347 6.9% 6.8% 0.1%
REMICADE
US 648 602 7.5% 7.5% -
Intl 171 174 -1.4% -1.4% -
WW 819 776 5.5% 5.5% -
TOPAMAX
US 498 435 14.4% 14.4% -
Intl 115 98 17.5% 9.7% 7.8%
WW 613 533 15.0% 13.6% 1.4%
Other
US 604 640 -5.6% -5.6% -
Intl 737 580 27.1% 18.1% 9.0%
WW 1,341 1,220 9.9% 5.6% 4.3%
Total Pharmaceutical Segment
US 3,765 3,841 -2.0% -2.0% -
Intl 2,334 2,040 14.4% 7.2% 7.2%
WW 6,099 5,881 3.7% 1.2% 2.5%
NINE MONTHS
% Change
2007 2006 Reported Operational(1) Currency
PHARMACEUTICAL SEGMENT (2)
ACIPHEX/PARIET
US 479 438 9.3% 9.3% -
Intl 531 483 9.9% 3.4% 6.5%
WW 1,010 921 9.7% 6.3% 3.4%
Anti-Psychotics (3)
US 2,037 1,788 13.9% 13.9% -
Intl 1,440 1,334 7.9% 1.8% 6.1%
WW 3,477 3,122 11.4% 8.8% 2.6%
CONCERTA
US 576 547 5.3% 5.3% -
Intl 163 125 30.5% 22.4% 8.1%
WW 739 672 10.0% 8.5% 1.5%
DURAGESIC
US 319 369 -13.8% -13.8% -
Intl 581 633 -8.2% -13.2% 5.0%
WW 900 1,002 -10.2% -13.4% 3.2%
EPREX/PROCRIT
US 1,359 1,573 -13.6% -13.6% -
Intl 898 819 9.6% 2.2% 7.4%
WW 2,257 2,392 -5.6% -8.1% 2.5%
Hormonal Contraceptives
US 516 597 -13.7% -13.7% -
Intl 194 175 11.3% 5.0% 6.3%
WW 710 772 -8.0% -9.4% 1.4%
LEVAQUIN/FLOXIN
US 1,155 1,048 10.2% 10.2% -
Intl 59 43 37.2% 36.5% 0.7%
WW 1,214 1,091 11.2% 11.2% 0.0%
REMICADE
US 1,873 1,763 6.3% 6.3% -
Intl 546 470 16.1% 16.1% 0.0%
WW 2,419 2,233 8.3% 8.3% 0.0%
TOPAMAX
US 1,471 1,200 22.5% 22.5% -
Intl 330 298 10.9% 4.0% 6.9%
WW 1,801 1,498 20.2% 18.8% 1.4%
Other
US 1,874 1,901 -1.4% -1.4% -
Intl 2,068 1,713 20.7% 13.1% 7.6%
WW 3,942 3,614 9.1% 5.5% 3.6%
Total Pharmaceutical Segment
US 11,659 11,224 3.9% 3.9% -
Intl 6,810 6,093 11.8% 5.6% 6.2%
WW 18,469 17,317 6.7% 4.5% 2.2%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Includes Risperdal, Risperdal Consta & Invega
REPORTED SALES vs. PRIOR PERIOD
$MM
THIRD QUARTER
% Change
2007 2006 Reported Operational(1) Currency
MEDICAL DEVICES AND DIAGNOSTICS (2)
Cordis
US 373 502 -25.6% -25.6% -
Intl 404 481 -16.3% -20.7% 4.4%
WW 777 983 -21.0% -23.1% 2.1%
DePuy
US 636 605 5.2% 5.2% -
Intl 450 366 22.9% 14.6% 8.3%
WW 1,086 971 11.9% 8.8% 3.1%
Ethicon
US 349 326 7.2% 7.2% -
Intl 528 470 12.1% 4.7% 7.4%
WW 877 796 10.1% 5.7% 4.4%
Ethicon Endo-Surgery
US 440 416 5.8% 5.8% -
Intl 482 409 17.7% 10.9% 6.8%
WW 922 825 11.7% 8.3% 3.4%
LifeScan
US 321 278 15.3% 15.3% -
Intl 264 227 16.8% 9.0% 7.8%
WW 585 505 16.0% 12.5% 3.5%
Ortho-Clinical Diagnostics
US 219 184 18.7% 18.7% -
Intl 185 176 5.4% -0.2% 5.6%
WW 404 360 12.2% 9.5% 2.7%
Total Vision Care
US 214 185 15.1% 15.1% -
Intl 363 308 18.5% 15.7% 2.8%
WW 577 493 17.2% 15.5% 1.7%
Other
US 17 13 30.8% 30.8% -
Intl 3 4 -25.0% -28.0% 3.0%
WW 20 17 17.6% 16.9% .7%
Total MD&D Segment
US 2,569 2,509 2.4% 2.4% -
Intl 2,679 2,441 9.8% 3.7% 6.1%
WW 5,248 4,950 6.0% 3.0% 3.0%
NINE MONTHS
% Change
2007 2006 Reported Operational(1) Currency
MEDICAL DEVICES AND DIAGNOSTICS (2)
Cordis
US 1,194 1,569 -23.9% -23.9% -
Intl 1,363 1,557 -12.5% -15.8% 3.3%
WW 2,557 3,126 -18.2% -19.9% 1.7%
DePuy
US 1,977 1,892 4.5% 4.5% -
Intl 1,401 1,153 21.5% 13.9% 7.6%
WW 3,378 3,045 10.9% 8.0% 2.9%
Ethicon
US 1,043 943 10.6% 10.6% -
Intl 1,605 1,443 11.2% 4.8% 6.4%
WW 2,648 2,386 11.0% 7.1% 3.9%
Ethicon Endo-Surgery
US 1,311 1,212 8.2% 8.2% -
Intl 1,459 1,264 15.4% 9.4% 6.0%
WW 2,770 2,476 11.9% 8.9% 3.0%
LifeScan
US 923 857 7.7% 7.7% -
Intl 807 675 19.6% 12.5% 7.1%
WW 1,730 1,532 13.0% 9.9% 3.1%
Ortho-Clinical Diagnostics
US 653 568 14.9% 14.9% -
Intl 550 530 3.7% -1.2% 4.9%
WW 1,203 1,098 9.5% 7.2% 2.3%
Total Vision Care
US 622 541 15.0% 15.0% -
Intl 1,021 867 17.8% 16.1% 1.7%
WW 1,643 1,408 16.7% 15.7% 1.0%
Other
US 49 37 32.4% 32.4% -
Intl 8 8 -% -2.5% 2.5%
WW 57 45 26.7% 26.0% .7%
Total MD&D Segment
US 7,772 7,619 2.0% 2.0% -
Intl 8,214 7,497 9.6% 4.3% 5.3%
WW 15,986 15,116 5.8% 3.2% 2.6%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
REPORTED SALES vs. PRIOR PERIOD
$MM
THIRD QUARTER
% Change
2007 2006 Reported Operational(1) Currency
CONSUMER SEGMENT (2) (3)
Skin Care
US 311 265 17.2% 17.2% -
Intl 426 370 15.1% 7.9% 7.2%
WW 737 635 16.0% 11.8% 4.2%
Baby & Kids Care
US 113 102 10.3% 10.3% -
Intl 398 349 14.2% 6.4% 7.8%
WW 511 451 13.3% 7.3% 6.0%
Oral Care
US 211 58 265.3% 265.3% -
Intl 185 38 383.5% 376.1% 7.4%
WW 396 96 312.3% 309.3% 3.0%
OTC/Nutritionals
US 653 481 36.0% 36.0% -
Intl 611 218 179.9% 172.5% 7.4%
WW 1,264 699 80.9% 78.6% 2.3%
Women's Health
US 149 151 -1.4% -1.4% -
Intl 312 281 11.2% 3.0% 8.2%
WW 461 432 6.8% 1.5% 5.3%
Other
US 154 81 90.1% 90.1% -
Intl 100 62 61.3% 53.3% 8.0%
WW 254 143 77.6% 74.2% 3.4%
Total Consumer Segment
US 1,591 1,138 39.8% 39.8% -
Intl 2,032 1,318 54.2% 46.5% 7.7%
WW 3,623 2,456 47.5% 43.4% 4.1%
NINE MONTHS
% Change
2007 2006 Reported Operational(1) Currency
Operational (1) Currency
CONSUMER SEGMENT (2) (3)
Skin Care
US 1,006 863 16.5% 16.5% -
Intl 1,252 1,085 15.4% 9.0% 6.4%
WW 2,258 1,948 15.9% 12.3% 3.6%
Baby & Kids Care
US 328 302 8.5% 8.5% -
Intl 1,117 977 14.4% 8.0% 6.4%
WW 1,445 1,279 13.0% 8.1% 4.9%
Oral Care
US 600 178 236.7% 236.7% -
Intl 509 115 342.2% 336.4% 5.8%
WW 1,109 293 278.1% 275.8% 2.3%
OTC/Nutritionals
US 1,892 1,340 41.3% 41.3% -
Intl 1,835 645 184.4% 177.7% 6.7%
WW 3,727 1,985 87.8% 85.6% 2.2%
Women's Health
US 475 448 6.1% 6.1% -
Intl 870 798 9.0% 2.2% 6.8%
WW 1,345 1,246 8.0% 3.7% 4.3%
Other
US 481 260 85.0% 85.0% -
Intl 318 198 60.6% 54.4% 6.2%
WW 799 458 74.5% 71.8% 2.7%
Total Consumer Segment
US 4,782 3,391 41.0% 41.0% -
Intl 5,901 3,818 54.6% 48.1% 6.5%
WW 10,683 7,209 48.2% 44.8% 3.4%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) 2007 Includes sales from acquisition of PCH